The MarketWatch News Department was not involved in the creation of this content. The Federal Trade Commission is sending more than $10.9 million to consumers harmed by a credit repair operation known ...
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...
A large VHA real-world analysis compared GLP‑1 receptor agonists (~132,000) with sulfonylureas (>201,000), focusing on major adverse cardiovascular outcomes in type 2 diabetes. Continuous GLP‑1 ...
Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. In early March the U.S. Food and Drug Administration sent a warning letter to Novo ...
Add Yahoo as a preferred source to see more of our stories on Google. Donald Trump is known for his hasty (and frequent) posts on social media. But in recent months, select posts have concluded with ...
Although one GLP-1 study made national headlines about the drug class’ potential use in addiction treatment, other research indicates GLP-1s could increase the risk of bone injuries and are less ...
There's new evidence that GLP-1 drugs like Ozempic can reduce the risk of addiction. A study of more than 600,000 veterans followed for up to three years found that those who started taking a GLP-1 ...
New data suggest a link between using GLP-1 receptor agonists (GLP-1 RAs) and a significantly higher risk for tendon ruptures, primarily tears involving the rotator cuff, Achilles, and pectoralis ...
Share on Pinterest GLP-1s linked to higher osteoporosis risk but they may bring some benefits, too, new studies find. Image credit: SweetBunFactory/Getty Images A large percentage of Americans are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results